Patents by Inventor Jutta Wanner

Jutta Wanner has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME
    Publication number: 20230000993
    Abstract: Described herein are silicon based conjugates capable of delivering one or more payload moieties to a target cell or tissue. Contemplated conjugates may include a silicon-heteroatom core, one or more optional catalytic moieties, a targeting moiety that permits accumulation of the conjugate within a target cell or tissue, one or more payload moieties (e.g., a therapeutic agent or imaging agent), and two or more non-interfering moieties covalently bound to the silicon-heteroatom core.
    Type: Application
    Filed: February 16, 2022
    Publication date: January 5, 2023
    Inventors: Kenneth W. Foreman, Hanh Nho Nguyen, Leslie Odame Ofori, Jutta Wanner, Douglas S. Werner
  • Silanol based therapeutic payloads
    Patent number: 11497757
    Abstract: Described herein in part are silanol based therapeutic payloads comprising a silanol terminus, a divalent spacer moiety, and a drug moiety capable of effecting a target cell or tissue.
    Type: Grant
    Filed: June 29, 2020
    Date of Patent: November 15, 2022
    Assignee: BlinkBio, Inc.
    Inventors: Hanh N. Nguyen, Leslie O. Ofori, Jutta Wanner, Douglas S. Werner
  • SILANOL BASED THERAPEUTIC PAYLOADS
    Publication number: 20220184104
    Abstract: Described herein in part are silanol based therapeutic payloads comprising a silanol terminus, a divalent spacer moiety, and a drug moiety capable of effecting a target cell or tissue.
    Type: Application
    Filed: February 24, 2022
    Publication date: June 16, 2022
    Inventors: Hanh Nho Nguyen, Leslie Odame Ofori, Jutta Wanner, Douglas S. Werner
  • Silicon based drug conjugates and methods of using same
    Patent number: 11291731
    Abstract: Described herein are silicon based conjugates capable of delivering one or more payload moieties to a target cell or tissue. Contemplated conjugates may include a silicon-heteroatom core, one or more optional catalytic moieties, a targeting moiety that permits accumulation of the conjugate within a target cell or tissue, one or more payload moieties (e.g., a therapeutic agent or imaging agent), and two or more non-interfering moieties covalently bound to the silicon-heteroatom core.
    Type: Grant
    Filed: February 6, 2018
    Date of Patent: April 5, 2022
    Assignee: BlinkBio, Inc.
    Inventors: Kenneth W. Foreman, Hanh N. Nguyen, Leslie O. Ofori, Jutta Wanner, Douglas S. Werner
  • Silanol Based Therapeutic Payloads
    Publication number: 20210161921
    Abstract: Described herein in part are silanol based therapeutic payloads comprising a silanol terminus, a divalent spacer moiety, and a drug moiety capable of effecting a target cell or tissue.
    Type: Application
    Filed: June 29, 2020
    Publication date: June 3, 2021
    Inventors: Hanh Nho Nguyen, Leslie Odame Ofori, Jutta Wanner, Douglas S. Werner
  • Silanol based therapeutic payloads
    Patent number: 10716801
    Abstract: Described herein in part are silanol based therapeutic payloads comprising a silanol terminus, a divalent spacer moiety, and a drug moiety capable of effecting a target cell or tissue.
    Type: Grant
    Filed: July 17, 2018
    Date of Patent: July 21, 2020
    Assignee: BlinkBio, Inc.
    Inventors: Hanh Nho Nguyen, Leslie Odame Ofori, Jutta Wanner, Douglas S. Werner
  • SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME
    Publication number: 20190290771
    Abstract: Described herein are silicon based conjugates capable of delivering one or more payload moieties to a target cell or tissue. Contemplated conjugates may include a silicon-heteroatom core, one or more optional catalytic moieties, a targeting moiety that permits accumulation of the conjugate within a target cell or tissue, one or more payload moieties (e.g., a therapeutic agent or imaging agent), and two or more non-interfering moieties covalently bound to the silicon-heteroatom core.
    Type: Application
    Filed: February 6, 2018
    Publication date: September 26, 2019
    Inventors: Kenneth W. Foreman, Hanh N. Nguyen, Leslie O. Ofori, Jutta Wanner, Douglas S. Werner
  • Silanol Based Therapeutic Payloads
    Publication number: 20190183913
    Abstract: Described herein in part are silanol based therapeutic payloads comprising a silanol terminus, a divalent spacer moiety, and a drug moiety capable of effecting a target cell or tissue.
    Type: Application
    Filed: July 17, 2018
    Publication date: June 20, 2019
    Inventors: Hanh Nho Nguyen, Leslie Odame Ofori, Jutta Wanner, Douglas S. Werner
  • Silanol based therapeutic payloads
    Patent number: 10293053
    Abstract: Described herein in part are silanol based therapeutic payloads comprising a silanol terminus, a divalent spacer moiety, and a drug moiety capable of effecting a target cell or tissue.
    Type: Grant
    Filed: December 18, 2018
    Date of Patent: May 21, 2019
    Assignee: BlinkBio, Inc.
    Inventors: Hanh N. Nguyen, Leslie O. Ofori, Jutta Wanner, Douglas S. Werner
  • Silanol Based Therapeutic Payloads
    Publication number: 20190111142
    Abstract: Described herein in part are silanol based therapeutic payloads comprising a silanol terminus, a divalent spacer moiety, and a drug moiety capable of effecting a target cell or tissue.
    Type: Application
    Filed: December 18, 2018
    Publication date: April 18, 2019
    Applicants: BlinkBio, Inc., BlinkBio, Inc.
    Inventors: Hanh N. Nguyen, Leslie O. Ofori, Jutta Wanner, Douglas S. Werner
  • Pyrazolo[1,5a]Pyrimidine Derivatives as IRAK4 Modulators
    Publication number: 20180298026
    Abstract: Compounds of the formula I or II: wherein X, m, Ar, R1 and R2 are as defined herein. The subject compounds are useful for treatment of IRAK-mediated conditions.
    Type: Application
    Filed: June 18, 2018
    Publication date: October 18, 2018
    Inventors: Nidhl Arora, Shaoqing Chen, Johannes Cornelius Hermann, Andreas Kuglstatter, Sharada Shenvi Labadie, Ciara Jeou Jen Lin, Matthew C. Lucas, Amy Geraldine Moore, Eva Papp, Francisco Xavier Talamas, Jutta Wanner, Yansheng Zhai
  • Silanol based therapeutic payloads
    Patent number: 10064880
    Abstract: Described herein in part are silanol based therapeutic payloads comprising a silanol terminus, a divalent spacer moiety, and a drug moiety capable of effecting a target cell or tissue.
    Type: Grant
    Filed: March 15, 2018
    Date of Patent: September 4, 2018
    Assignee: BlinkBio, Inc.
    Inventors: Hanh N. Nguyen, Leslie O. Ofori, Jutta Wanner, Douglas S. Werner
  • Silanol Based Therapeutic Payloads
    Publication number: 20180200273
    Abstract: Described herein in part are silanol based therapeutic payloads comprising a silanol terminus, a divalent spacer moiety, and a drug moiety capable of effecting a target cell or tissue.
    Type: Application
    Filed: March 15, 2018
    Publication date: July 19, 2018
    Inventors: Hanh N. Nguyen, Leslie O. Ofori, Jutta Wanner, Douglas S. Werner
  • Pyrazolo[1,5a]pyrimidine derivatives as IRAK4 modulators
    Patent number: 10023589
    Abstract: Compounds of the formula I or II: wherein X, m, Ar, R1 and R2 are as defined herein. The subject compounds are useful for treatment of IRAK-mediated conditions.
    Type: Grant
    Filed: December 18, 2015
    Date of Patent: July 17, 2018
    Assignees: Hoffmann-La Roche Inc., Roche Palo Alto LLC
    Inventors: Nidhi Arora, Shaoqing Chen, Johannes Cornelius Hermann, Andreas Kuglstatter, Sharada Shenvi Labadie, Clara Jeou Jen Lin, Matthew C. Lucas, Amy Geraldine Moore, Eva Papp, Francisco Xavier Talamas, Jutta Wanner, Yansheng Zhai
  • Silicon based drug conjugates and methods of using same
    Patent number: 9931407
    Abstract: Described herein are silicon based conjugates capable of delivering one or more payload moieties to a target cell or tissue. Contemplated conjugates may include a silicon-heteroatom core, one or more optional catalytic moieties, a targeting moiety that permits accumulation of the conjugate within a target cell or tissue, one or more payload moieties (e.g., a therapeutic agent or imaging agent), and two or more non-interfering moieties covalently bound to the silicon-heteroatom core.
    Type: Grant
    Filed: April 3, 2017
    Date of Patent: April 3, 2018
    Assignee: BlinkBio, Inc.
    Inventors: Kenneth W. Foreman, Hanh N. Nguyen, Leslie O. Ofori, Jutta Wanner, Douglas S. Werner
  • SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME
    Publication number: 20170202970
    Abstract: Described herein are silicon based conjugates capable of delivering one or more payload moieties to a target cell or tissue. Contemplated conjugates may include a silicon-heteroatom core, one or more optional catalytic moieties, a targeting moiety that permits accumulation of the conjugate within a target cell or tissue, one or more payload moieties (e.g., a therapeutic agent or imaging agent), and two or more non-interfering moieties covalently bound to the silicon-heteroatom core.
    Type: Application
    Filed: April 3, 2017
    Publication date: July 20, 2017
    Inventors: Kenneth W. Foreman, Hanh N. Nguyen, Leslie O. Ofori, Jutta Wanner, Douglas S. Werner
  • PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS
    Publication number: 20160207936
    Abstract: Compounds of the formula I or II: wherein X, m, Ar, R1 and R2 are as defined herein. The subject compounds are useful for treatment of IRAK-mediated conditions.
    Type: Application
    Filed: December 18, 2015
    Publication date: July 21, 2016
    Inventors: Nidhi Arora, Shaoqing Chen, Johannes Cornelius Hermann, Andreas Kuglstatter, Sharada Shenvi Labadie, Ciara Jeou Jen Lin, Matthew C. Lucas, Amy Geraldine Moore, Eva Papp, Francisco Xavier Talamas, Jutta Wanner, Yansheng Zhai
  • Pyrazolo[1,5a]pyrimidine derivatives as IRAK4 modulators
    Patent number: 9255110
    Abstract: Compounds of the formula I or II: wherein X, m, Ar, R1 and R2 are as defined herein. The subject compounds are useful for treatment of IRAK-mediated conditions.
    Type: Grant
    Filed: April 2, 2014
    Date of Patent: February 9, 2016
    Assignees: ROCHE PALO ALTO LLC, HOFFMANN-LA ROCHE INC.
    Inventors: Nidhi Arora, Shaoqing Chen, Johannes Cornelius Hermann, Andreas Kuglstatter, Sharada Shenvi Labadie, Clara Jeou Jen Lin, Matthew C. Lucas, Amy Geraldine Moore, Eva Papp, Francisco Xavier Talamas, Jutta Wanner, Yansheng Zhai
  • Imidazopyridazine compounds
    Patent number: 9169259
    Abstract: The present invention relates to the use of novel compounds of formula I: wherein all variable substituents are defined as described herein, which are SYK inhibitors and are useful for the treatment of auto-immune and inflammatory diseases.
    Type: Grant
    Filed: October 31, 2012
    Date of Patent: October 27, 2015
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Johannes Cornelius Hermann, Andreas Kuglstatter, Matthew C. Lucas, Fernando Padilla, Jutta Wanner, Xiaohu Zhang
  • PYRROLOPYRAZONE INHIBITORS OF TANKYRASE
    Publication number: 20150011556
    Abstract: There are provided compounds of the formula wherein R1 and R2 are as described herein. The compounds are useful as anticancer agents.
    Type: Application
    Filed: September 22, 2014
    Publication date: January 8, 2015
    Applicant: HOFFMANN-LA ROCHE INC.
    Inventors: Johannes Hermann, Ann Catherine Petersen, Jutta Wanner, Lin Yi